Check-Cap Ltd - Asset Resilience Ratio
Check-Cap Ltd (7CC) has an Asset Resilience Ratio of 2.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Check-Cap Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Check-Cap Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Check-Cap Ltd.
Liquid Assets Composition Over Time
This chart breaks down Check-Cap Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Check-Cap Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €217.00K | 2.9% |
| Total Liquid Assets | €217.00K | 2.90% |
Asset Resilience Insights
- Limited Liquidity: Check-Cap Ltd maintains only 2.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Check-Cap Ltd Industry Peers by Asset Resilience Ratio
Compare Check-Cap Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medpace Holdings Inc
NASDAQ:MEDP |
Diagnostics & Research | 0.00% |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Check-Cap Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Check-Cap Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.90% | €217.00K ≈ $253.70K |
€7.49 Million ≈ $8.75 Million |
-60.71pp |
| 2023-12-31 | 63.60% | €15.91 Million ≈ $18.60 Million |
€25.02 Million ≈ $29.25 Million |
-19.16pp |
| 2022-12-31 | 82.76% | €37.61 Million ≈ $43.97 Million |
€45.44 Million ≈ $53.13 Million |
+37.66pp |
| 2021-12-31 | 45.10% | €25.10 Million ≈ $29.35 Million |
€55.66 Million ≈ $65.07 Million |
-6.22pp |
| 2020-12-31 | 51.32% | €10.08 Million ≈ $11.78 Million |
€19.64 Million ≈ $22.96 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€9.43 Million ≈ $11.02 Million |
-- |
| 2018-12-31 | 36.56% | €5.64 Million ≈ $6.60 Million |
€15.44 Million ≈ $18.05 Million |
-- |
About Check-Cap Ltd
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology for the detection of precancerous colorectal polyps. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.